A nine-octapeptide insertional mutation in the prion protein (PrP) causes a fatal neurodegenerative disorder in both humans and transgenic mice. To determine the precise cellular localization of this mutant PrP (designated PG14), we have generated transgenic mice expressing PG14-EGFP, a fluorescent fusion protein that can be directly visualized in vivo. Tg(PG14-EGFP) mice develop an ataxic neurological illness characterized by astrogliosis, PrP aggregation, and accumulation of a partially protease-resistant form of the mutant PrP. Strikingly, PG14-EGFP forms numerous fluorescent aggregates in the neuropil and white matter of multiple brain regions. These aggregates are particularly prominent along axonal tracts in both brain and peripheral nerve, and similar intracellular deposits are visible along the processes of cultured neurons. Our results reveal intra-axonal aggregates of a mutant PrP, which could contribute to the pathogenesis of familial prion disease by disrupting axonal transport.
Introduction
Prions are infectious proteins associated with several fatal neurodegenerative diseases in mammals (Prusiner, 2004) . Prion diseases result from conversion of the cellular prion protein (PrP C ) into a conformationally altered isoform (PrP Sc ) that is aggregated and protease-resistant. Dominantly inherited mutations in the gene encoding PrP are responsible for familial forms of prion disease (Kong et al., 2004) . One mutant, designated PG14, harbors a nineoctapeptide repeat insertion in the N-terminal region of PrP that is associated with ataxia, dementia, and cerebellar PrP plaques in several families (Duchen et al., 1993; Krasemann et al., 1995; Owen et al., 1992) . Tg(PG14) mice expressing the mouse homolog of the PG14 mutant develop an ataxic neurological illness characterized by non-amyloid PrP deposits, apoptosis of cerebellar granule neurons, and loss of synaptophysin-positive nerve terminals (Chiesa et al., 2000 (Chiesa et al., , 2005 (Chiesa et al., , 1998 .
Elucidating the mechanisms by which PG14 and other mutant PrPs induce neuropathology requires information about the localization of these molecules at the anatomical and subcellular levels. However, immunolocalization of PG14 PrP deposits in brain tissue has proven to be technically challenging due to the poor antibody reactivity of the mutant protein as a result of conformational changes and/or aggregation. Like PrP Sc , PG14 PrP possesses hidden epitopes that prevent antibody recognition without the use of harsh antigen retrieval techniques, such as hydrolytic autoclaving or treatment with guanidine thiocyanate (Kitamoto et al., 1987 (Kitamoto et al., , 1992 Van Everbroeck et al., 1999) . However, these techniques, which denature or partially hydrolyze proteins, necessarily introduce a number of potential artifacts.
Our previous immunohistochemical studies identified punctate, most likely extracellular deposits of PG14 PrP in the cerebellum and other brain regions of Tg(PG14) mice (Chiesa et al., 2000 (Chiesa et al., , 1998 . However, intracellular aggregates of the protein in neuronal cell bodies or axons were never observed. This result is surprising, given the known cellular trafficking patterns of PrP along secretory, endocytic and axonal transport pathways (Harris, 2003) , as well as our own previous observation that mutant PrP molecules are partially retained in the endoplasmic reticulum of cultured cells (Ivanova et al., 2001 ). These considerations suggest that conventional immunohistochemical methods may be providing an incomplete picture of the localization of PG14 in brain tissue.
To overcome the limitations of immunocytochemical detection, we have developed lines of transgenic mice expressing PrP-EGFP, a fusion protein incorporating enhanced green fluorescent protein (EGFP) inserted near the C-terminal, glycolipid attachment site of PrP. In mice that express PrP-EGFP incorporating wild-type (WT) PrP, the fluorescent protein is correctly synthesized and posttranslationally modified, and is distributed in an anatomic and subcellular pattern similar to that of untagged PrP (Barmada et al., 2004) . In addition, the fusion protein retains functional activity, 
